| abstract |
The present invention relates to the combination therapy of pyruvoyl analogs and anti-oxidants, and cytokines that cause markedly increased microglial activity and inflammatory response compared to the administration of each substance alone. In addition to inhibiting the activity of the brain tissue by inhibiting the activity of the damage, and the ability to improve the motor capacity and neurological damage, as well as 6 hours after the onset of the damage can continue to exhibit a high neuroprotective effect. |